A Thursday ruling, issued on the court’s emergency docket and without stated reasoning, placed a stay on the manufacturers’ case. This order halts proceedings until the justices determine whether to grant full review. The stay will remain active throughout this decision-making process.
The Supreme Court has temporarily restored broad access to the abortion pill mifepristone, blocking a recent ruling that had sought to impose new restrictions. This order allows the pill to be obtained through pharmacies or mail, bypassing previous in-person visit requirements. This decision is significant as medication abortions, typically using mifepristone and misoprostol, are the primary method for abortions in the U.S. and have been a crucial factor in circumventing abortion bans enacted by Republican-led states. The Supreme Court will further consider the issue in the coming week.
A federal appeals court has issued a ruling that significantly restricts access to mifepristone, a common abortion medication in the U.S., by blocking its mailing. The three-judge panel’s decision requires the drug to be distributed only in person at clinics, overriding previous Food and Drug Administration regulations. This ruling, likely to be appealed to the Supreme Court, represents a major shift in abortion policy and could impact access nationwide, even in states where abortion is legal.
US Health Secretary Robert F. Kennedy Jr. has directed the FDA to review mifepristone regulations based on new data from a flawed, non-peer-reviewed analysis. This analysis, promoted by anti-abortion groups, alleges higher complication rates than previously known, prompting calls to reinstate prior restrictions or remove the drug entirely. The data significantly overstates risks, including misclassifying ectopic pregnancies as complications of mifepristone. Anti-abortion groups intend to use this analysis to pressure the FDA and lawmakers to severely limit mifepristone access, potentially through ending telemedicine prescriptions as a first step. Despite over 100 studies confirming mifepristone’s safety and effectiveness, this campaign aims to significantly restrict access to the abortion pill.
Judge Matthew Kacsmaryk ruled that Idaho, Kansas, and Missouri can proceed with a lawsuit aiming to restrict access to mifepristone. The states seek to limit telehealth prescriptions, shorten the gestational limit for use, and mandate in-person visits, arguing these measures are necessary to uphold state abortion laws. The ACLU criticized the decision, viewing it as an attack on medication abortion. This case follows a previous ruling by Kacsmaryk against mifepristone and comes amidst ongoing efforts by multiple states to further restrict access to abortion pills. The outcome could significantly impact abortion access nationwide.
John Q. Hosedrinker